Saint Therese of Oxbow Lake Earns 2025 Zellner Group Client of the Year Award
Brooklyn Park, MN senior care community recognized for exceptional partnership, leadership, and commitment to resident-centered care ST LOUIS PARK, MN...
Day: January 20, 2026
Saint Therese of Oxbow Lake Earns 2025 Zellner Group Client of the Year Award
Brooklyn Park, MN senior care community recognized for exceptional partnership, leadership, and commitment to resident-centered care ST LOUIS PARK, MN...
Saint Therese of Oxbow Lake Earns 2025 Zellner Group Client of the Year Award
Brooklyn Park, MN senior care community recognized for exceptional partnership, leadership, and commitment to resident-centered care ST LOUIS PARK, MN...
Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial
Pathology data indicate 70% overall response rate for squamous cell carcinomas: 100% clearance in 10 out of 14 responders Favorable...
Adia Nutrition Inc. Receives Notification from SEC: Form 10 to Become Effective on February 3, 2026
Winter Park, Florida--(Newsfile Corp. - January 20, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and...
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA
EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIsNow commercially available through retail pharmacies and participating Aytu...
Black Book Research Releases “New Zealand Acute Care EMR & Digital Health 2026” Companion Report
New analysis details the national platforms, standards, and vendor landscape shaping EMR consolidation, interoperability, medicines safety, and cyber resilience across...
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
This patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combination as a method to topically treat...
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam – Generic Xanax(R) – for Rapid Anxiety Relief
New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and generalized anxiety disordersAlprazolam, sold...
Akanda Announces $7.0 Million Convertible Note Offering
Toronto, Ontario--(Newsfile Corp. - January 20, 2026) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company") today announced the execution of a...
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)
Study subject Remains in Complete Response for 3 YearsExceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent...
Functional Brands Inc. Introduces Kirkman(R) Detox Aid Bundle: a Comprehensive Approach to Heavy Metal and General Detoxification Support
Lake Oswego, Oregon--(Newsfile Corp. - January 20, 2026) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and...
Safe Supply Announces Sale of NIRLAB Drug Analysis Device to Far North Resources Inc., Advancing Indigenous-Led Community Safety and Rapid Drug Identification
Toronto, Ontario--(Newsfile Corp. - January 20, 2026) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe...
Therma Bright Sells an Additional 200-Units of Venowave(TM) to Strategic Distribution Partner Gen-X Med
Toronto, Ontario--(Newsfile Corp. - January 20, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma Bright" or...
VSI® Performs World’s First Bertolotti Resection Surgery Utilizing Augmented Reality
Breakthrough technique by VSI Spine Surgeon Dr. Colin Haines advances a new global standard for precision bone removal and rapid...
EQT Life Sciences co-leads EUR 51 million Series B in Exciva to advance its Alzheimer’s therapy into clinical Phase 2
Series B financing will support Exciva's Phase 2 clinical trial of its lead candidate, Deraphan, for agitation associated with Alzheimer's...
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the...